3.00
0.00%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About HighTide Therapeutics
Its shares trade on HKEX under the ticker 2511.HK. It has been listed since 22 December 2023.
HighTide Therapeutics Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2023-12-22. HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The firm has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The firm conducts operations in the United States, Mainland China, Hong Kong and Australia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Dec 2023
- Website
- hightidetx.com ↗
Leadership
Pay as last reported
- Dr. Liping LiuExecutive Chairwoman of the Board, Chief Executive Officer, Founder, since 2018CN¥7.5m
- Mr. Koon Yin SimChief Financial Officer
- Dr. Tianwei MaVice President of Discovery Research
- Ms. Li YuVice President
- Ms. Meng YuDeputy General Manager, Executive Director, since 2017
- Ms. Ru BaiDirector of Non-Clinical Development
- Dr. Anne Macconell LeighChief Development Officer
- Ms. Pik Man ChuJoint Company Secretary
- Ms. Liping GaoJoint Company Secretary
- Mr. Feng JiangNon-Executive Director
- Mr. Lixiong MaNon-Executive DirectorCN¥838,000
- Dr. Xun ZhuNon-Executive Director, since 2020CN¥2.2m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 85
- Environment
- 92
- Social
- 93
- Governance
- 71
- Direct emissions (scope 1)
- 25,755 t
- Energy emissions (scope 2)
- 205,292 t
- Value chain emissions (scope 3)
- 125,441 t
- Women in the workforce
- 53%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- HighTide Therapeutics Inc specializes in metabolic and digestive disease therapies with HTD1801 as core product.
- The company operates in multiple regions including United States, Mainland China, Hong Kong, and Australia.
- HighTide Therapeutics Inc has an in-house developed product pipeline covering multiple indications.
Weaknesses
- The company is a new entrant with IPO on 22 December 2023.
- HighTide Therapeutics Inc has limited commercialization experience in the biopharmaceutical sector.
- The firm's product pipeline includes only clinical-stage candidates without approved products.
Opportunities
- HighTide Therapeutics Inc can expand its product pipeline in metabolic and digestive diseases.
- The growing global market for metabolic and digestive disease treatments offers significant opportunities.
- The company's operations in Mainland China provide access to a large patient population.
Threats
- HighTide Therapeutics Inc faces competition from established biopharmaceutical companies.
- The biopharmaceutical industry is subject to regulatory challenges and clinical trial risks.
- The company's reliance on clinical-stage products exposes it to development delays and failures.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.